A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

NCT00947167 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Extreme toxicity of Pertuzumab and Erlotinib combination

Conditions

Neuroendocrine Tumors
Carcinoid Tumors
Adrenal Gland Tumors
Neuroblastoma
Pancreatic Neuroendocrine Tumors
Multiple Endocrine Neoplasia

Interventions

DRUG: pertuzumab
DRUG: erlotinib

Sponsor

Pamela L. Kunz

Collaborators

[object Object]